证券代码：603858 证券简称：步长制药 公告编号：2025-194 山东步长制药股份有限公司 关于控股子公司签订技术服务合同的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，山东步长制药股份有限公司（以下简称"公司"）控股子公司四川泸 州步长生物制药有限公司（以下简称"泸州步长"）与苏州药明康德新药开发有 限公司（以下简称"药明康德"）签订《技术服务合同》，委托药明康德进行药 代动力学和毒理学试验项目。现将具体内容公告如下： 一、《技术服务合同》的主要内容 甲方：四川泸州步长生物制药有限公司 乙方：苏州药明康德新药开发有限公司 （一）项目内容、技术内容、范围和要求 1、甲方向乙方提供本项目技术内容、范围和要求，乙方以报价单的形式向 甲方提供报价。 2、报价单对双方具有约束力，如报价单中内容与本合同约定不一致的，应 当优先适用报价单条款。 （二）技术服务费的支付方式 1、如本合同履行过程中，甲方要求增加可选项目或其他服务内容的，双方 应就增加的服务内容达成新的报价单或补充协议。增加的服务内容未经双方书面 确认，乙方 ...

本次泸州步长与第三方签订《技术服务合同》，有利于扩大公司药品研发能力和范围，一定程度上节约 了公司药品临床试验的时间和成本，保障项目的顺利进行。 格隆汇10月16日丨步长制药(603858.SH)公布，公司控股子公司四川泸州步长生物制药有限公司（称"泸 州步长"）与苏州药明康德新药开发有限公司（称"药明康德"）签订《技术服务合同》，委托药明康德 进行药代动力学和毒理学试验项目。合同总金额为1080万元，含6%税费，甲方将依合同约定分期支付 相关费用。 ...

Core Viewpoint - The company has signed a technical service contract with WuXi AppTec for pharmacokinetics and toxicology testing, which will enhance its drug development capabilities and efficiency [1] Group 1: Contract Details - The total amount of the contract is 10.8 million yuan, including a 6% tax [1] - Payments will be made in installments as per the contract agreement [1] Group 2: Strategic Implications - This collaboration is expected to expand the company's drug research and development capacity [1] - It aims to reduce the time and cost associated with clinical trials, ensuring the smooth progress of projects [1]

Core Insights - The announcement of POMDOCTOR LIMITED's listing on NASDAQ marks a significant milestone for the company, enhancing its cash flow and shareholder return capabilities [1] - The transformation of the company is not merely an addition of product categories but involves a strategic focus on high-value patented areas and a robust R&D pipeline [2] - The company has committed to social responsibility through extensive public welfare initiatives, which complement its capital strategies aimed at enhancing shareholder value [3][5] Group 1: Financial and Market Developments - The company holds approximately 15% of POMDOCTOR LIMITED's total shares post-IPO, indicating a strong financial position [1] - The company has increased its R&D investment from 512 million to 717 million RMB over three years, achieving a compound annual growth rate of about 18%, surpassing the industry average [2] - Cumulative share repurchases since 2016 amount to nearly 1.8 billion RMB, positioning the company as a leader in shareholder returns within the traditional Chinese medicine sector [3] Group 2: R&D and Product Development - The company has optimized its patent structure, with 474 effective patents and 17 new invention patents expected by 2025, supporting its innovation strategy [2] - The R&D pipeline includes 209 projects across traditional Chinese medicine, chemical drugs, biological products, and vaccines, indicating a comprehensive approach to product development [2] - The company is actively developing 12 biological products, with some already in the NDA application stage, and has four vaccine products available, with five more in development [2] Group 3: Social Responsibility and Community Engagement - The company has executed the "Together, Build China's Heart" public welfare project for 18 consecutive years, benefiting over one million people in Tibet and surrounding areas [3] - Initiatives include training for over 10,000 medical personnel and providing free surgeries for over 3,700 children with congenital heart disease [3][5] - The company has invested in local agricultural projects to support farmers, significantly improving their income and living standards [5]

Group 1 - Mindray Medical plans to issue H-shares and list on the Hong Kong Stock Exchange, aiming to broaden financing channels and enhance international influence for global business expansion and R&D [1] Group 2 - Shandong Buchang Pharmaceutical's investee company, Shiliu Yunyi, listed on NASDAQ using the VIE model, with an estimated market value of approximately $474 million on its first trading day, expected to positively impact Buchang's financials by 2025 [2] Group 3 - CSPC Pharmaceutical's subsidiary, CSPC Baike, received acceptance for the new drug application of Idaglutide α injection, which selectively activates GLP-1 receptors to aid weight loss and improve blood sugar and cardiovascular metrics, potentially capturing market share in the GLP-1 sector [3]

Core Viewpoint - The company announced that its associate, Guangzhou Qilekang Digital Health Medical Technology Co., Ltd., has a substantial controlling company, POMDOCTOR LIMITED, which will be listed on the NASDAQ under the ticker symbol POM on October 8, 2025 [1] Group 1 - The listing will utilize the VIE (Variable Interest Entity) structure [1]

Core Viewpoint - The company, Bichang Pharmaceutical (603858.SH), has received approval from the National Medical Products Administration for its Ibuprofen Sustained-Release Capsules, indicating a significant advancement in its product offerings [1]. Group 1: Product Approval - Bichang Pharmaceutical's wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., has been granted a Drug Registration Certificate for Ibuprofen Sustained-Release Capsules [1]. - The approved indication for the Ibuprofen Sustained-Release Capsules includes relief for mild to moderate pain such as headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea [1]. - Additionally, the capsules are indicated for fever caused by common colds or influenza [1].

Core Viewpoint - The announcement by the company regarding the approval of Ibuprofen sustained-release capsules by the National Medical Products Administration indicates a significant development in its product portfolio, aimed at addressing various types of pain and fever associated with common illnesses [1] Company Summary - The company, Bicheng Pharmaceutical, has received a drug registration certificate for Ibuprofen sustained-release capsules from the National Medical Products Administration [1] - The approved indication for the drug includes relief from mild to moderate pain such as headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and dysmenorrhea, as well as fever caused by common colds or influenza [1] Industry Summary - The approval of this medication aligns with the growing demand for effective pain management solutions in the pharmaceutical industry, particularly for over-the-counter medications [1] - The introduction of Ibuprofen sustained-release capsules may enhance competition within the pain relief segment of the pharmaceutical market [1]

Core Viewpoint - The company BuChang Pharmaceutical (603858.SH) announced that its associate company, Guangzhou Qilekang Digital Health Medical Technology Co., Ltd. (referred to as "Qilekang Digital Medical"), will be listed on the NASDAQ under the VIE model on October 8, 2025, with the stock code POM [1] Group 1 - The substantial controlling company of Qilekang Digital Medical, POMDOCTOR LIMITED, is also known as "Shiliu Yunyi" [1] - After the global offering, BuChang Pharmaceutical, through its wholly-owned subsidiary DanHong (H.K.) Technology Limited, will hold 2,957,613 shares of Shiliu Yunyi, representing approximately 15% of the total share capital post-issuance [1]

山东步长制药股份有限公司（以下简称"本公司"）参股公司广州七乐康数 字健康医疗科技有限公司（以下简称"七乐康数字医疗"）的实质控股公司 POMDOCTOR LIMITED 石榴云医有限公司（以下简称"石榴云医"）于 2025 年 10 月 8 日（美国纽约时间）以 VIE 模式在美国纳斯达克证券交易所挂牌上市，股份 代码：POM。石榴云医美国上市的详细内容可在美国证券交易委员会和美国纳斯达 克证券交易所网站查阅。 二、持股情况 石榴云医本次全球发售完成后，本公司通过全资子公司 Dan Hong (H.K.) Technology Limited 丹红（香港）科技有限公司持有上市主体石榴云医的股份数 为 2,957,613 股，占石榴云医发行完成后总股本约 15%。 三、对七乐康数字医疗股权的会计处理方式及影响 根据《企业会计准则》相关规定，公司对所持石榴云医的股权划分为"以公 允价值计量且其变动计入当期损益的金融资产"，并列报在"交易性金融资产"。 石榴云医上市事项预计对公司 2025 年财务状况与经营成果将产生积极影响，具体 影响最终以会计师年度审计确认后的结果为准。敬请广大投资者理性投资，注意 投资风险。 ...